In order to support this pharmacokinetic behavior of the bivalent tracer [64Cu]Cu-α-EGFR-EGFR–NODAGA TM, time-activity curves (TAC) of regions of interest (ROI) derived from dynamic PET studies of four analyzed A431-Luc tumor bearing mice were estimated. This evidence concerns the gene EGFR and neoplasm.